Cited by 256Psychedelics and Drug StudiesTreatment of Major DepressionReligion, Spirituality, and Psychology

The DOI matches its Crossref record; 126 of the 127 references it cites were found in a registry or an index.

Classical psychedelics for the treatment of depression and anxiety: A systematic review

Muttoni, Silvia, Ardissino, Maddalena, John, Christopher·2019·Journal of Affective Disorders

DOI 10.1016/j.jad.2019.07.076

Open this paper in CoChat — free account

Abstract

Background Depression and anxiety are prevalent psychiatric disorders that carry significant morbidity. Pharmacological and psychosocial interventions are used to manage these conditions, but their efficacy is limited. Recent interest into the use of psychedelic-assisted therapy using ayahuasca, psilocybin or lysergic acid diethylamide (LSD) may be a promising alternative for patients unresponsive to traditional treatments. This review aims to determine the efficacy and tolerability of psychedelics in the management of resistant depression.Methods Clinical trials investigating psychedelics in patients with depression and/or anxiety were searched via MEDLINE, EMBASE and PsychINFO. Efficacy was assessed by measuring symptom improvement from baseline, and tolerability was evaluated by noting the incidence and type of adverse effects reported. Risk of bias was assessed.Results Seven studies, with 130 patients, were analysed in this review. Three were conducted in patients with depression, two in patients with anxiety and two in patients with both. In a supportive setting, ayahuasca, psilocybin, and LSD consistently produced immediate and significant anti-depressant and anxiolytic effects that were endured for several months. Psychedelics were well-tolerated. The most common adverse effects were transient anxiety, short-lived headaches, nausea and mild increases in heart rate and blood pressure.Limitations At present, the number of studies on this subject is very limited; and the number of participating patients within these is also limited as the treatment under investigations is a relatively novel concept.Conclusions Though further evidence is required, psychedelics appear to be effective in significantly reducing symptoms of depression and anxiety and are well-tolerated.

Integrity signals

Registry

Crossref · 10.1016/j.jad.2019.07.076

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Proceedings of the National Academy of Sciences of the United States of America
Dowling, J. E., & Wald, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06752.x · Cited by 17,937
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947
Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies
Mitchell, A. J., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen, C., & Meader, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70002-x · Cited by 2,449
Resting-State Functional Connectivity in Major Depression: Abnormally Increased Contributions from Subgenual Cingulate Cortex and Thalamus
Greicius, M. D., Flores, B. H., Menon, V., Glover, G. H., Solvason, H. B., Kenna, H., Reiss, A. L., & Schatzberg, A. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.020 · Cited by 2,214
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201

Show all 127 references

Research works printed but not linked: 3

Fava, 2003, 53, 649
Mcintyre, 2004, Young mania rating scale (YMRS), Can. J. Clin. Pharmacol., 11
Johnson, 2008, Human hallucinogen research: guidelines for safety, J. Psychopharmacol., 22, 603, 10.1177/0269881108093587 · DOI · Paper page

Sorted by citations

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J. S., Salam, I., Neill, J. C., & Nutt, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 359
Psychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Ko, K., Kopra, E. I., Cleare, A. J., & Rucker, J. J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.168 · Cited by 150
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis
Roméo, B., Karila, L., Martelli, C., & Benyamina, A. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120919957 · Cited by 122
Case analysis of long-term negative psychological responses to psychedelics
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41145-x · Cited by 128
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
The Neuropsychology of Anxiety
McNaughton, N., & Gray, J. A. (2024) · doi:10.1093/oso/9780198843313.001.0001 · Cited by 99
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
Why was early therapeutic research on psychedelic drugs abandoned?
Hall, W. (2021) · Psychological Medicine · doi:10.1017/s0033291721004207 · Cited by 98
Depression, mindfulness, and psilocybin: possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. a review
Heuschkel, K., & Kuypers, K. P. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00224 · Cited by 86
Novel antidepressant drugs: Beyond monoamine targets
Gonda, X., Döme, P., Neill, J. C., & Tarazi, F. I. (2021) · CNS Spectrums · doi:10.1017/s1092852921000791 · Cited by 83
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
Rootman, J. M., Kryskow, P., Harvey, K., Stamets, P. E., Santos-Brault, E., Kuypers, K. P. C., Polito, V., Bourzat, F., & Walsh, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-01811-4 · Cited by 90
Classics in Chemical Neuroscience: Amitriptyline
McClure, E. W., & Daniels, R. N. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00467 · Cited by 75
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Untitled work
Giluk (2009) · doi:10.1017/s003329172000389x · Cited by 68
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 73
Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
Pattern breaking: a complex systems approach to psychedelic medicine
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad017 · Cited by 70
The psychedelic afterglow phenomenon: A systematic review of subacute effects of classic serotonergic psychedelics
Evens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231172254 · Cited by 56
“Two symptom-specific reviews reported subacute effects separately from long-term effects and observed rapid antidepressant 17,18 and anxiolytic effects 17 after psychedelic use that were largely sustained also in more extended follow-up periods.”
Background
Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
Hashimoto, K. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01770-7 · Cited by 58
Rethinking therapeutic strategies for anorexia nervosa: insights from psychedelic medicine and animal models
Foldi, C. J., Liknaitzky, P., Williams, M., & Oldfield, B. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00043 · Cited by 51
Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects
Durante, Í., SANTOS, R. G. D., Bouso, J. C., & Hallak, J. E. C. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0913 · Cited by 59
Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice
Pędzich, B. D., Rubens, S., Sekssaoui, M., Pierre, A., Schuerbeek, A. V., Marin, P., Bockaert, J., Valjent, E., Bécamel, C., & Bundel, D. D. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01324-2 · Cited by 51
Psychedelics and virtual reality: parallels and applications
Aday, J. S., Davoli, C. C., & Bloesch, E. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320948356 · Cited by 47
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 52
Mindfulness meditation and psychedelics: potential synergies and commonalities
Holas, P., & Kamińska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00551-8 · Cited by 43
“Classic psychedelics, such as synthetic LSD and psilocybin, which is found in certain mushrooms, have shown promise as aids in psychotherapy e.g., for mood disorders and substance dependence [1, 5, 33].”
Background
Do psychedelics change beliefs?
McGovern, H. T., Leptourgos, P., Hutchinson, B. T., & Corlett, P. R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06153-1 · Cited by 40
Catalysts for change: the cellular neurobiology of psychedelics
Banks, M. I., Zahid, Z., Jones, N., Sultan, Z. W., & Wenthur, C. J. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-05-0340 · Cited by 45
A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders
Kisely, S. R., Connor, M. A., Somogyi, A. A., & Siskind, D. J. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221083868 · Cited by 46
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 40
Psychedelics for treatment resistant depression: are they game changers?
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2281582 · Cited by 37
Trends in the Top-Cited Articles on Classic Psychedelics
Lawrence, D. W., Sharma, B., Griffiths, R. R., & Carhart-Harris, R. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1874573 · Cited by 35
Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Prouzeau, D., Conejero, I., Voyvodic, P. L., Bécamel, C., Abbar, M., & López‐Castromán, J. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01361-0 · Cited by 37
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Meling, D., Ehrenkranz, R. C., Nayak, S. M., Aicher, H., Funk, X., van Elk, M., Graziosi, M., Bauer, P. R., Scheidegger, M., & Yaden, D. B. (2024) · Psychoactives · doi:10.3390/psychoactives3020014 · Cited by 35
Efficacité des psychédéliques en psychiatrie, une revue systématique
Berkovitch, L., Roméo, B., Karila, L., Gaillard, R., & Benyamina, A. (2021) · L Encéphale · doi:10.1016/j.encep.2020.12.002 · Cited by 35
Beating pain with psychedelics: Matter over mind?
Elman, I., Pustilnik, A. C., & Borsook, D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.005 · Cited by 30
Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing
Dougherty, R. F., Clarke, P., Atli, M., Kuc, J., Schlosser, D. A., Dunlop, B. W., Hellerstein, D. J., Aaronson, S. T., Zisook, S., Young, A. H., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06432-5 · Cited by 29
Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center
Rush, B. R., Marcus, O., García, S., Loizaga-Velder, A. K., Loewinger, G. C., Spitalier, A., & Mendive, F. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.659644 · Cited by 32
Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use
Perkins, D., Ruffell, S., Day, K., Rubiano, D. P., & Sarris, J. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.879221 · Cited by 33
Psilocybin in Palliative Care: An Update
Whinkin, E., Opalka, M., Watters, C., Jaffe, A., & Aggarwal, S. K. (2023) · Current Geriatrics Reports · doi:10.1007/s13670-023-00383-7 · Cited by 33
Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study
Kaup, K., Vasser, M., Tulver, K., Munk, M., Pikamäe, J., & Aru, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1088896 · Cited by 31
Psychedelic Science, Contemplative Practices, and Indigenous and Other Traditional Knowledge Systems: Towards Integrative Community-Based Approaches in Global Health
Urrutia, J., Anderson, B. T., Belouin, S. J., Berger, A. M., Griffiths, R. R., Grob, C. S., Henningfield, J. E., Labate, B. C., Maier, L. J., Maternowska, M. C., et al. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2258367 · Cited by 29
Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis
Bahji, A., Lunsky, I. O., Gutiérrez, G., & Vázquez, G. H. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2278586 · Cited by 32
Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis
Hsu, T., Tsai, C., Kao, Y., Thompson, T., Carvalho, A. F., Yang, F., Tseng, P., Hsu, C.-W., Yu, C., Tu, Y., et al. (2024) · BMJ · doi:10.1136/bmj-2023-078607 · Cited by 28
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey
Bonnelle, V., Smith, W., Mason, N. L., Cavarra, M., Kryskow, P., Kuypers, K. P. C., Ramaekers, J. G., & Feilding, A. (2022) · British Journal of Pain · doi:10.1177/20494637221114962 · Cited by 26
Use of Lysergic Acid Diethylamide by Major Depression Status
Walsh, C. A., Gorfinkel, L., Shmulewitz, D., Stohl, M., & Hasin, D. S. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.3867 · Cited by 26
New agents and perspectives in the pharmacological treatment of major depressive disorder
Sanches, M., Quevedo, J., & Soares, J. C. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110157 · Cited by 26
Psychedelia: The interplay of music and psychedelics
Jerotic, K., Vuust, P., & Kringelbach, M. L. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15082 · Cited by 27
A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review
Wong, S., Kwan, A. T. H., Teopiz, K. M., Le, G. H., Meshkat, S., Ho, R., d’Andrea, G., Cao, B., Vincenzo, J. D. D., Rosenblat, J. D., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.142 · Cited by 24
Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology
Shinozuka, K., Jerotic, K., Mediano, P. A. M., Zhao, A. T., Preller, K. H., Carhart-Harris, R. L., & Kringelbach, M. L. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03187-1 · Cited by 28
The psychedelic effects of cannabis: A review of the literature
Wolinsky, D., Barrett, F. S., & Vandrey, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231209194 · Cited by 26
Acceptance and Commitment Therapy Among Informal Caregivers of People With Chronic Health Conditions: A Systematic Review and Meta-Analysis
Ye, F., Lee, J. J., Xue, D., & Yu, D. S.-F. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.46216 · Cited by 23
Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia
Nadeem, Z., Parker, S., McGovern, H. T., & Oestreich, L. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241261779 · Cited by 23
The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies
Low, Z. X. B., Ng, W. S., Lim, E. S. Y., Goh, B. H., & Kumari, Y. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111139 · Cited by 22
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Meling, D., & Scheidegger, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1100058 · Cited by 22
Psilocybin’s Potential Mechanisms in the Treatment of Depression: A Systematic Review
Lee, H. J., Tsang, V. W. L., Chai, B. S., Lin, M. C., Howard, A. K., Uy, C. E., & Elefante, J. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2223195 · Cited by 21
Self-Actualization and the Integration of Psychedelic Experience: The Mediating Role of Perceived Benefits to Narrative Self-Functioning
Amada, N. M., & Shane, J. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221099680 · Cited by 19
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Kaypak, A. C., & Raz, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119386 · Cited by 22
Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness
Forstmann, M., Kettner, H., Sagioglou, C., Irvine, A., Gandy, S., Carhart-Harris, R. L., & Luke, D. P. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221146356 · Cited by 21
Insights, Life Changes and Lifestyle Changes Reported by Individuals Consuming Ayahuasca in Naturalistic Settings: Nature, Frequency and Associations with Mental Health and Wellbeing
Perkins, D., Opaleye, E. S., Bouso, J. C., Tófoli, L. F., Sarris, J. J., Schubert, V., Ruffell, S., & Šimonová, H. (2023) · Psychoactives · doi:10.3390/psychoactives2040017 · Cited by 21
Psychedelic risks and benefits: A cross-sectional survey study
Goldy, S. P., Du, B. A., Rohde, J. S., Nayak, S. M., Strickland, J. C., Ehrenkranz, R. C., Levine, M., Barrett, F. S., & Yaden, D. B. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241292951 · Cited by 18
Entropy and Complexity Tools Across Scales in Neuroscience: A Review
Cofré, R., & Alain Destexhe, A. (2025) · Entropy · doi:10.3390/e27020115 · Cited by 21
Enhancing Hopeful Resilience Regarding Depression and Anxiety with a Narrative Method of Ordering Memory Effective in Researchers Experiencing Burnout
Nash, C. (2022) · Challenges · doi:10.3390/challe13020028 · Cited by 21
Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials
Wang, S., Kim, S., Choi, W.-S., Lim, H. K., Woo, Y. S., Pae, C., & Bahk, W. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1134 · Cited by 19
Personality traits explain the relationship between psychedelic use and less depression in a comparative study
Sjöström, D. K., Claesdotter‐Knutsson, E., & Kajonius, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-60890-1 · Cited by 18
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review
da Cruz, R. V. L., Leão, R. N., & Moulin, T. C. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01013-4 · Cited by 19
Psychédéliques, psychothérapie et symbolisation : une revue de littérature dans le champ de la dépression
Artru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 20
Developmental Neurotoxicity Screen of Psychedelics and Other Drugs of Abuse in Larval Zebrafish ( Danio rerio )
Tombari, R. J., Mundy, P. C., Morales, K. M., Dunlap, L. E., Olson, D. E., & Lein, P. J. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00642 · Cited by 18
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat
Meling, D., Egger, K., Aicher, H., Redondo, J. J., Mueller, J., Dornbierer, J., Temperli, E., Vasella, E. A., Caflisch, L., Pfeiffer, D., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241282637 · Cited by 20
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
Zeiss, R., Gahr, M., & Graf, H. (2021) · Pharmaceuticals · doi:10.3390/ph14100985 · Cited by 20
Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey
Daldegan‐Bueno, D., Révész, D., Morais, P. R., Barbosa, P. C. R., & Maia, L. O. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2063896 · Cited by 20
Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users
Fauvel, B., Kangaslampi, S., Strika-Bruneau, L., Roméo, B., & Piolino, P. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2059796 · Cited by 36
Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
Castillo, A., Dubois, J., Field, R. M., Fishburn, F. A., Gundran, A., Ho, W. C., Jawhar, S., Kates‐Harbeck, J., Aghajan, Z. M., Miller, N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38258-8 · Cited by 16
Perspectives on psychedelic treatment and research in eating disorders: a web-based questionnaire study of people with eating disorders
Harding, F., Seynaeve, M., Keeler, J. L., Himmerich, H., Treasure, J. L., & Kan, C. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2003059 · Cited by 16
The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
Rossi, G. N., Hallak, J. E. C., Baker, G. B., Dursun, S. M., & SANTOS, R. G. D. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01460-2 · Cited by 16
Utilizing Psychedelics to Enhance Well-Being: A Systematic Review
Thomson, S., & Thomacos, N. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2484380 · Cited by 16
Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis
Marchi, M., Farina, R., Rachedi, K., Laonigro, F., Žuljević, M. F., Pingani, L., Ferrari, S., Somers, M., Boks, M. P., & Galeazzi, G. M. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303594 · Cited by 17
Effectiveness of Psilocybin on Depression: A Qualitative Study
Alshaikhli, H., Al-Naggar, R. A., & Erlam, G. D. (2021) · Electronic Journal of General Medicine · doi:10.29333/ejgm/10862 · Cited by 21
Pharmacotherapy of anxiety disorders in the 21st century: A call for novel approaches
Bui, É., King, F., & Melaragno, A. (2019) · General Psychiatry · doi:10.1136/gpsych-2019-100136 · Cited by 17
Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers
Rossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Oña, G., Silveira, G. D. O., Yonamine, M., Bertozi, G., Crevelin, E. J., Queiroz, M. E. C., et al. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001691 · Cited by 14
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience
Nicholas, C. R. N., Banks, M. I., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R., Hutson, P. R., Sauder, C. J., Dunne, J. D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03059-8 · Cited by 13
Psychedelics and connectedness to natural and social worlds: An examination of the evidence and a proposed conceptual framework
Forstmann, M., & Sagioglou, C. (2025) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2025.101992 · Cited by 15
Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review
Kuburi, S., Passa, A.-M. D., Tassone, V. K., Mahmood, R., Lalovic, A., Ladha, K. S., Dunlop, K., Rizvi, S. J., Demchenko, I., & Bhat, V. (2022) · Chronic Stress · doi:10.1177/24705470221115342 · Cited by 14
The Potential Role of Serotonergic Hallucinogens in Depression Treatment
Psiuk, D., Nowak, E., Cholewa, K., Łopuszańska, U., & Samardakiewicz, M. (2021) · Life · doi:10.3390/life11080765 · Cited by 12
A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents
Bogadi, M., & Kaštelan, S. (2021) · Croatian Medical Journal · doi:10.3325/cmj.2021.62.528 · Cited by 13
Pattern Breaking: A Complex Systems Approach to Psychedelic MedicinePreprint
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2022) · doi:10.31234/osf.io/ydu3h · Cited by 13
Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications
Galdino, T. P., Oliveira, L. C., Luz, M. A., Jesus, R. A., Lima, E. P. N., Torres, M. C. M., Sivieri, K., Afonso, V. I., Delgado, J. M. P. Q., Lima, A. G. B., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030380 · Cited by 12
Schedule 1 barriers to research in the UK: An in-depth qualitative analysis
Howard, A., Neill, J. C., Schlag, A. K., & Lennox, C. (2021) · Drug Science Policy and Law · doi:10.1177/20503245211049313 · Cited by 12
Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish
Hagen, E. V., Schalomon, M., Zhang, Y., & Hamilton, T. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-54676-8 · Cited by 12
Single administration of a psychedelic [(R)-DOI] influences coping strategies to an escapable social stress
Krupp, K. T., Yaeger, J. D. W., Ledesma, L. J., Withanage, M. H. H., Gale, J., Howe, C. B., Allen, T. J., Sathyanesan, M., Newton, S. S., & Summers, C. H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109949 · Cited by 12
Psychedelic use and psychological flexibility: The role of meaningful intention and decentering
Campo, W. M., & Yali, A. M. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00350 · Cited by 12
Fast Hollow Fiber Liquid-Phase Microextraction as a Greener Alternative for the Determination of N,N-Dimethyltryptamine and Harmala Alkaloids in Human Urine
Silveira, G. D. O., Lourenço, F. R., Bruno, V., & Yonamine, M. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.558501 · Cited by 14
Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics
Kojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 12
β-carboline-independent antidepressant-like effect of the standardized extract of the barks of Mimosa tenuiflora (Willd) Poir. occurs via 5-HT 2A/2C receptors in mice
Filho, L. A. M. D. S. D., Amariz, I. A. E., Nishimura, R. H. V., Massaranduba, A. B. R., Menezes, P. M. N., Damasceno, T. A., Brys, I., Rolim, L. A., Silva, F. S., & Ribeiro, L. A. D. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221104050 · Cited by 12
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“To date, reviews have focused on establishing treatment efficacy [30], understanding the neurological mechanisms of change [71], or have been broad in their aims (e.”
A continuum hypothesis of psychotomimetic rapid antidepressants
Haarsma, J., Harmer, C. J., & Tamm, S. (2021) · Brain and Neuroscience Advances · doi:10.1177/23982128211007772 · Cited by 13
Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences
Shaw, L., Rea, K., Lachowsky, N. J., & Roth, E. A. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2054746 · Cited by 11

Authors: Muttoni, S., Ardissino, M., & John, C.
Affiliations: Imperial College London (GB)
Chelsea and Westminster Hospital (GB)
Corresponding author: Ardissino, Maddalena
ORCID: Ardissino, Maddalena
John, Christopher
Venue: Journal of Affective Disorders
Publisher: Elsevier BV
Published: 2019-11
Volume: 258
Pages: 11-24
ISSN: 0165-0327 (ISSN-L)
DOI: 10.1016/j.jad.2019.07.076
OpenAlex: W2964775179
Cited by: 256
References: 127
Citations by year: 2026: 19 · 2025: 34 · 2024: 67 · 2023: 51 · 2022: 31 · 2021: 32 · 2020: 20 · 2019: 2
FWCI: 3.35
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Affective Disorders (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords: psychedelics, psychedelic therapy, depression, anxiety, treatment-resistant depression, ayahuasca, psilocybin, lysergic acid diethylamide, treatment efficacy, tolerability, adverse effects
MeSH terms: Adult, Anxiety Disorders, Depressive Disorder, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Classical psychedelics for the treatment of depression and anxiety: A systematic review

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks